Table 1.

Decision Model Parameters

	Base Case	Low	High	Source
Population Distribution (true condition)
No/Mild Fibrosis	69%	67%	71%	Poynard 200412
Moderate/High Fibrosis	31%	33%	29%	Poynard 200412
Fibrosure Test Characteristics
Probabilities for patients with no/mild fibrosis
Test positive	13%	11%	15%	Poynard et al 200412
Test indeterminate	19%	17%	21%	Poynard et al 200412
Test negative	68%	64%	72%	Poynard et al 200412
Probabilities for patients with moderate/severe fibrosis
Test positive	56%	54%	58%	Poynard et al 200412
Test indeterminate	28%	26%	30%	Poynard et al 200412
Test negative	16%	12%	20%	Poynard et al 200412
Fibrospect II Characteristics
Probabilities for patients with no/mild fibrosis
Test positive	29%	21%	36%	Prometheus Labs13
Test indeterminate	0%	-	-
Test negative	71%	67%	75%	Prometheus Labs13
Probabilities for patients with moderate/severe fibrosis
Test positive	81%	60%	100%	Prometheus Labs13
Test indeterminate	0%	-	-
Test negative	19%	15%	23%	Prometheus Labs13
Fibroscan Test Characteristics
Probabilities for patients with no/mild fibrosis
Test positive	11%	8%	14%	Castera et al.14
Test indeterminate	0%	-	-
Test negative	89%	85%	93%	Castera et al.14
Probabilities for patients with moderate/severe fibrosis
Test positive	67%	50%	84%	Castera et al.14
Test indeterminate	0%	-	-
Test negative	33%	29%	37%	Castera et al.14
Costs*
Fibrosure Test	$215	$161	$269	Labcorp personal communication 4/01/06
Liver Biopsy	$1,255	$941	$1,569	Wong et al, 199823
Fibrospect II	$350	$263	$438	Botts et al, 200524
Fibroscan	$131	$98	$164	CEDIT, 200425

^*Adjusted to 2005 US dollars using medical care component of Consumer Price Index